mayo clinic glp 1 program Companion for GLP-1s Mayo Clinic Minute: Weight loss
Description
We will name the trade-offs
KZ: Writing review & editing
Heres what I conclude: GLP-1 microdosing and off-label use occupy an uncomfortable gray zone - strong mechanistic rationale, consistent observational patterns, but limited controlled human data
While generally beneficial, these drugs can cause an increase in heart rate for certain patients
Gerstein HC, Hart R, Colhoun HM, Diaz R, Lakshmanan M, Botros FT, et al
Oral semaglutide is generally considered for individuals with a Body Mass Index (BMI) of 30 or higher, or a BMI of 27 or higher when accompanied by weight-related health concerns
